Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Finished Goods (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Finished Goods for 3 consecutive years, with $15.5 million as the latest value for Q1 2025.

  • On a quarterly basis, Finished Goods rose 153.3% to $15.5 million in Q1 2025 year-over-year; TTM through Mar 2025 was $15.5 million, a 153.3% increase, with the full-year FY2024 number at $15.0 million, up 224.72% from a year prior.
  • Finished Goods was $15.5 million for Q1 2025 at Iovance Biotherapeutics, up from $15.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $15.5 million in Q1 2025 to a low of $1.1 million in Q2 2023.
  • A 3-year average of $7.9 million and a median of $5.5 million in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: skyrocketed 224.72% in 2024, then surged 153.3% in 2025.
  • Iovance Biotherapeutics' Finished Goods stood at $4.6 million in 2023, then surged by 224.72% to $15.0 million in 2024, then grew by 3.55% to $15.5 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Finished Goods are $15.5 million (Q1 2025), $15.0 million (Q4 2024), and $6.1 million (Q1 2024).